X-Chem, Bayer deal

X-Chem and Bayer expanded their 2012 drug discovery deal to include multiple undisclosed therapeutic areas and target classes. The companies said the new arrangement “will significantly expand the scope and duration of the partnership.” Bayer said it will now have greater access to X-Chem’s DEX library of DNA-encoded small molecules that enable the identification of lead candidates against difficult targets. ...